378 related articles for article (PubMed ID: 34333002)
21. Relevance of weight in the management of patients with type 2 diabetes mellitus: towards an adipocentric approach to diabetes.
Gorgojo Martínez JJ
Med Clin (Barc); 2016 Nov; 147 Suppl 1():8-16. PubMed ID: 28760227
[TBL] [Abstract][Full Text] [Related]
22. The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes.
Kim GS; Park JH; Won JC
Endocrinol Metab (Seoul); 2019 Jun; 34(2):106-116. PubMed ID: 31099200
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Cardiol; 2017 Jul; 120(1S):S17-S27. PubMed ID: 28606340
[TBL] [Abstract][Full Text] [Related]
24. Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications.
Abdul-Ghani MA; Jayyousi A; DeFronzo RA; Asaad N; Al-Suwaidi J
Curr Vasc Pharmacol; 2019; 17(2):153-163. PubMed ID: 29032755
[TBL] [Abstract][Full Text] [Related]
25. What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?
Lovre D; Htun W; Carrion C; Fonseca VA
Curr Diab Rep; 2016 Oct; 16(10):94. PubMed ID: 27541296
[TBL] [Abstract][Full Text] [Related]
26. Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States.
Mody R; Meyers J; Yu M; Davis K; Levine JA
Curr Med Res Opin; 2022 Nov; 38(11):1785-1795. PubMed ID: 35758147
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
28. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease Prevention.
Reid J; Rana K; Niman S; Sheikh-Ali M; Lewis T; Choksi RR; Goldfaden RF
Am J Cardiovasc Drugs; 2020 Oct; 20(5):419-429. PubMed ID: 32043244
[TBL] [Abstract][Full Text] [Related]
29. Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus.
Jung CH; Mok JO
Endocrinol Metab (Seoul); 2020 Jun; 35(2):260-271. PubMed ID: 32615710
[TBL] [Abstract][Full Text] [Related]
30. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists.
Bonaventura A; Carbone S; Dixon DL; Abbate A; Montecucco F
J Intern Med; 2019 Jul; 286(1):16-31. PubMed ID: 30888088
[TBL] [Abstract][Full Text] [Related]
31. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
Budd J; Cusi K
Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
[TBL] [Abstract][Full Text] [Related]
32. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
Basile JN
J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Thrasher J
Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
[TBL] [Abstract][Full Text] [Related]
34. Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society.
Napoli R; Avogaro A; Formoso G; Piro S; Purrello F; Targher G; Consoli A
Nutr Metab Cardiovasc Dis; 2021 Nov; 31(12):3257-3270. PubMed ID: 34627692
[TBL] [Abstract][Full Text] [Related]
35. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
Tanaka A; Node K
Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290
[TBL] [Abstract][Full Text] [Related]
36. A review of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor cardiovascular trials: Implications for practice.
Battise DM; Olin JL
J Am Assoc Nurse Pract; 2021 Mar; 33(12):1139-1147. PubMed ID: 33105320
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
Scheen AJ
Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
[TBL] [Abstract][Full Text] [Related]
38. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
[TBL] [Abstract][Full Text] [Related]
39. Glucose-Lowering Medications and Cardiovascular Outcomes.
Shanmugasundaram M; Pineda JRE; Murugapandian S
Curr Cardiol Rep; 2021 Mar; 23(4):24. PubMed ID: 33655453
[TBL] [Abstract][Full Text] [Related]
40. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F
Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]